JP2004504295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004504295A5 JP2004504295A5 JP2002512124A JP2002512124A JP2004504295A5 JP 2004504295 A5 JP2004504295 A5 JP 2004504295A5 JP 2002512124 A JP2002512124 A JP 2002512124A JP 2002512124 A JP2002512124 A JP 2002512124A JP 2004504295 A5 JP2004504295 A5 JP 2004504295A5
- Authority
- JP
- Japan
- Prior art keywords
- shvd
- hydroxyvitamin
- stabilized
- composition
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000036740 Metabolism Effects 0.000 description 3
- 229940046008 Vitamin D Drugs 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000035786 metabolism Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002062 proliferating Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N Methyl formate Chemical group COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- 230000035507 absorption Effects 0.000 description 1
- FKCBLVCOSCZFHV-UHFFFAOYSA-N acetonitrile;ethanol Chemical compound CCO.CC#N FKCBLVCOSCZFHV-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- QKGYJVXSKCDGOK-UHFFFAOYSA-N hexane;propan-2-ol Chemical compound CC(C)O.CCCCCC QKGYJVXSKCDGOK-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000640 hydroxylating Effects 0.000 description 1
- 230000003463 hyperproliferative Effects 0.000 description 1
- 230000001678 irradiating Effects 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- -1 vitamin D compound Chemical class 0.000 description 1
- 150000003710 vitamin D derivatives Chemical group 0.000 description 1
- 150000003722 vitamin derivatives Chemical group 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
Description
【特許請求の範囲】
【請求項1】純度が質量ベースのHPLC分析によって98%以上であり、残留溶媒が0.5%以下であり、合計不純物が1.5%以下であり、及び、0.5%より大きい単一の不純物を有しないことを特徴とする、安定化1α−ヒドロキシビタミンD(SHVD)。
【請求項2】不純物が、1α−ヒドロキシビタミンD4である、請求項1に記載の安定化1α−ヒドロキシビタミンD。
【請求項3】熱攻撃におけるビタミンD形態からプレビタミン形態への転換率が、同一条件下での非安定化1α−ヒドロキシビタミンD(非SHVD2)より低い、請求項1に記載の安定化1α−ヒドロキシビタミンD。
【請求項4】請求項1に記載のSHVDを含む医薬組成物。
【請求項5】ソフトゼラチンカプセルである請求項4に記載の組成物。
【請求項6】溶液である、請求項4に記載の組成物。
【請求項7】単位投与形態であり、0.5μg〜25μgの活性成分を含む、請求項4に記載の組成物。
【請求項8】油中、請求項1に記載のSHVDの効果的量の溶液を含み、該溶液が、ソフトゼラチンカプセルに含まれている組成物。
【請求項9】油が分画されたココナッツ油である、請求項8に記載の組成物。
【請求項10】請求項1に記載のSHVDの効果的な量の固体医薬製剤を含み、該固体医薬製剤が、タブレット、カプセル、粒剤、粉体の形態である組成物。
【請求項11】活性成分としての請求項1に記載のSHVDの効果的量を含む、カルシウム吸収、輸送または代謝、高増殖細胞活性、免疫応答不均衡または炎症応答不均衡の異常性が原因の病気の治療用薬剤。
【請求項12】病気が乾癬である、請求項11に記載の薬剤。
【請求項13】 活性成分としての請求項1に記載のSHVDの効果的量を、治療が必要なヒト以外の被検者に投与することを含む、カルシウム吸収、輸送または代謝、高増殖細胞活性、免疫応答不均衡または炎症応答不均衡の異常性が原因の病気の治療方法。
【請求項14】熱攻撃のときの1α−ヒドロキシプレビタミンDへの転化率が、同一条件下での非SHVDと比較して減少することを特徴とする、安定化1α−ヒドロキシビタミンD(SHVD)。
【請求項15】熱攻撃が、約60℃の一定温度で起こる、請求項14に記載の安定化1α−ヒドロキシビタミンD。
【請求項16】実質的に純粋で、実質的に溶媒フリーで、かつ貯蔵安定性である、安定化1α−ヒドロキシビタミンD(SHVD)。
【請求項17】対応するプレビタミン形態と比較して実質的に減少した転換率によって特徴付けられる安定化1α−ヒドロキシビタミンD(SHVD)を含む、医薬化合物。
【請求項18】(a)ビタミンD化合物である出発物質の3位のヒドロキシル基をトシル化してヒドロキシを1α位に加える工程;
(b)トシル化形態をシクロビタミンに転換する工程;
(c)1α位のシクロビタミンをヒドロキシル化する工程;
(d)シクロビタミンをシス及びトランスビタミン形態に転換する工程;
(e)トランスビタミン形態を照射してシス形態を生成する工程;
(f)シス形態を、有機溶媒中で再結晶化し、再結晶化形態を72〜120時間55℃で真空オーブン乾燥してSHVDを生成する工程、
を含む、安定化1α−ヒドロキシビタミンD(SHVD)の製造方法。
【請求項19】請求項18に記載の方法によって合成される、安定化1α−ヒドロキシビタミンD(SHVD)。
【請求項20】少なくとも3回、粗製のヒドロキシビタミンD製品を有機溶媒から連続的に再結晶化することを含む、安定化1α−ヒドロキシビタミンD(SHVD)の製造方法。
【請求項21】再結晶化方法が、2つの再結晶化を含む、請求項20に記載の方法。
【請求項22】有機溶媒が、ギ酸メチル、ギ酸エチル、酢酸エチル、アセトン、メチルエチルケトン、ヘキサン、2-プロパノール-ヘキサン、ペンタン、ヘプタン、ジエチルエーテル、ジイソプロピルエーテル、メタノール、エタノールアセトニトリル又はその組み合わせである、請求項21に記載の方法。
【請求項23】 カルシウム吸収、輸送または代謝、高増殖細胞活性、免疫応答不均衡または炎症応答不均衡の異常性が原因の病気の治療用組成物の製造における、活性成分としての請求項1に記載のSHVDの効果的量の使用。
【請求項1】純度が質量ベースのHPLC分析によって98%以上であり、残留溶媒が0.5%以下であり、合計不純物が1.5%以下であり、及び、0.5%より大きい単一の不純物を有しないことを特徴とする、安定化1α−ヒドロキシビタミンD(SHVD)。
【請求項2】不純物が、1α−ヒドロキシビタミンD4である、請求項1に記載の安定化1α−ヒドロキシビタミンD。
【請求項3】熱攻撃におけるビタミンD形態からプレビタミン形態への転換率が、同一条件下での非安定化1α−ヒドロキシビタミンD(非SHVD2)より低い、請求項1に記載の安定化1α−ヒドロキシビタミンD。
【請求項4】請求項1に記載のSHVDを含む医薬組成物。
【請求項5】ソフトゼラチンカプセルである請求項4に記載の組成物。
【請求項6】溶液である、請求項4に記載の組成物。
【請求項7】単位投与形態であり、0.5μg〜25μgの活性成分を含む、請求項4に記載の組成物。
【請求項8】油中、請求項1に記載のSHVDの効果的量の溶液を含み、該溶液が、ソフトゼラチンカプセルに含まれている組成物。
【請求項9】油が分画されたココナッツ油である、請求項8に記載の組成物。
【請求項10】請求項1に記載のSHVDの効果的な量の固体医薬製剤を含み、該固体医薬製剤が、タブレット、カプセル、粒剤、粉体の形態である組成物。
【請求項11】活性成分としての請求項1に記載のSHVDの効果的量を含む、カルシウム吸収、輸送または代謝、高増殖細胞活性、免疫応答不均衡または炎症応答不均衡の異常性が原因の病気の治療用薬剤。
【請求項12】病気が乾癬である、請求項11に記載の薬剤。
【請求項13】 活性成分としての請求項1に記載のSHVDの効果的量を、治療が必要なヒト以外の被検者に投与することを含む、カルシウム吸収、輸送または代謝、高増殖細胞活性、免疫応答不均衡または炎症応答不均衡の異常性が原因の病気の治療方法。
【請求項14】熱攻撃のときの1α−ヒドロキシプレビタミンDへの転化率が、同一条件下での非SHVDと比較して減少することを特徴とする、安定化1α−ヒドロキシビタミンD(SHVD)。
【請求項15】熱攻撃が、約60℃の一定温度で起こる、請求項14に記載の安定化1α−ヒドロキシビタミンD。
【請求項16】実質的に純粋で、実質的に溶媒フリーで、かつ貯蔵安定性である、安定化1α−ヒドロキシビタミンD(SHVD)。
【請求項17】対応するプレビタミン形態と比較して実質的に減少した転換率によって特徴付けられる安定化1α−ヒドロキシビタミンD(SHVD)を含む、医薬化合物。
【請求項18】(a)ビタミンD化合物である出発物質の3位のヒドロキシル基をトシル化してヒドロキシを1α位に加える工程;
(b)トシル化形態をシクロビタミンに転換する工程;
(c)1α位のシクロビタミンをヒドロキシル化する工程;
(d)シクロビタミンをシス及びトランスビタミン形態に転換する工程;
(e)トランスビタミン形態を照射してシス形態を生成する工程;
(f)シス形態を、有機溶媒中で再結晶化し、再結晶化形態を72〜120時間55℃で真空オーブン乾燥してSHVDを生成する工程、
を含む、安定化1α−ヒドロキシビタミンD(SHVD)の製造方法。
【請求項19】請求項18に記載の方法によって合成される、安定化1α−ヒドロキシビタミンD(SHVD)。
【請求項20】少なくとも3回、粗製のヒドロキシビタミンD製品を有機溶媒から連続的に再結晶化することを含む、安定化1α−ヒドロキシビタミンD(SHVD)の製造方法。
【請求項21】再結晶化方法が、2つの再結晶化を含む、請求項20に記載の方法。
【請求項22】有機溶媒が、ギ酸メチル、ギ酸エチル、酢酸エチル、アセトン、メチルエチルケトン、ヘキサン、2-プロパノール-ヘキサン、ペンタン、ヘプタン、ジエチルエーテル、ジイソプロピルエーテル、メタノール、エタノールアセトニトリル又はその組み合わせである、請求項21に記載の方法。
【請求項23】 カルシウム吸収、輸送または代謝、高増殖細胞活性、免疫応答不均衡または炎症応答不均衡の異常性が原因の病気の治療用組成物の製造における、活性成分としての請求項1に記載のSHVDの効果的量の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21906800P | 2000-07-18 | 2000-07-18 | |
PCT/US2001/022729 WO2002006218A2 (en) | 2000-07-18 | 2001-07-18 | STABILIZED 1α-HYDROXY VITAMIN D |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004504295A JP2004504295A (ja) | 2004-02-12 |
JP2004504295A5 true JP2004504295A5 (ja) | 2008-09-04 |
Family
ID=22817719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002512124A Pending JP2004504295A (ja) | 2000-07-18 | 2001-07-18 | 安定化1α−ヒドロキシビタミンD |
Country Status (7)
Country | Link |
---|---|
US (2) | US6903083B2 (ja) |
EP (2) | EP2070911A2 (ja) |
JP (1) | JP2004504295A (ja) |
AU (2) | AU2001278956B2 (ja) |
CA (1) | CA2414407A1 (ja) |
IL (2) | IL153378A0 (ja) |
WO (1) | WO2002006218A2 (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
AU2001278956B2 (en) * | 2000-07-18 | 2007-04-05 | Genzyme Corporation | Stabilized 1alpha-hydroxy vitamin d |
EP1461044A4 (en) * | 2001-12-03 | 2007-06-13 | Novacea Inc | PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE COMPOUNDS OF VITAMIN D |
US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
EP1458678A1 (en) * | 2002-11-18 | 2004-09-22 | Teva Pharmaceutical Industries Limited | A crystallization method for purification of calcipotriene |
US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
JP2005247803A (ja) * | 2004-03-08 | 2005-09-15 | Zeria Pharmaceut Co Ltd | 点眼剤及びその容器 |
ATE469127T1 (de) * | 2004-11-22 | 2010-06-15 | Wisconsin Alumni Res Found | 17,20(z)-dehydro-vitamin-d-analoge und deren verwendungen |
CA2924200C (en) * | 2005-10-12 | 2017-09-05 | Proventiv Therapeutics, Llc | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency |
SI3095447T1 (sl) | 2006-02-03 | 2022-02-28 | Opko Renal, Llc | Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3 |
JP5204088B2 (ja) * | 2006-03-17 | 2013-06-05 | レオ ファーマ アクティーゼルスカブ | 医薬中間体の異性化 |
PT2679228T (pt) * | 2006-06-21 | 2018-04-16 | Opko Ireland Global Holdings Ltd | Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d |
CA2669914C (en) * | 2006-11-16 | 2017-11-07 | Kai Pharmaceuticals, Inc. | Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders |
PL2148684T3 (pl) * | 2007-04-25 | 2013-06-28 | Cytochroma Inc | Sposób leczenia niedoboru i deficytu witaminy D |
EP3335712A1 (en) * | 2007-04-25 | 2018-06-20 | Opko Renal, LLC | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
PT2148661E (pt) | 2007-04-25 | 2013-03-06 | Proventiv Therapeutics Llc | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso |
EP2148685A4 (en) * | 2007-04-25 | 2010-07-28 | Cytochroma Inc | METHODS AND COMPOUNDS FOR THERAPY BASED ON VITAMIN D |
WO2009086437A1 (en) * | 2007-12-28 | 2009-07-09 | Wisconsin Alumni Research Foundation | (20r)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs |
MX2010007266A (es) * | 2007-12-28 | 2010-11-30 | Wisconsin Alumni Res Found | Análogos de vitamina d, (20s)-23, 23-difluoro-2-metilen-19-nor-bis homopregnacalciferol. |
JP5492099B2 (ja) * | 2008-03-12 | 2014-05-14 | シトクロマ インコーポレイテッド | 安定化1,25−ジヒドロキシビタミンd2及びその製造方法 |
CN106853250A (zh) | 2008-04-02 | 2017-06-16 | 赛特克罗公司 | 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒 |
US8013176B2 (en) * | 2008-09-11 | 2011-09-06 | Alphora Research Inc. | Paricalcitol purification |
US20120130133A1 (en) * | 2008-11-26 | 2012-05-24 | Cytochroma Inc. | Method For Synthesizing Vitamin D Analogs |
SG10201406921SA (en) | 2009-07-29 | 2014-11-27 | Kai Pharmaceuticals Inc | Therapeutic agents for reducing parathyroid hormone levels |
PT2552484T (pt) | 2010-03-29 | 2020-04-03 | Opko Ireland Global Holdings Ltd | Métodos e composições para redução dos níveis de parafróides |
CA2698160C (en) * | 2010-03-30 | 2017-07-25 | Alphora Research Inc. | Stabilized doxercalciferol and process for manufacturing the same |
US20120108554A1 (en) * | 2010-10-28 | 2012-05-03 | Formosa Laboratories, Inc. | PROCESS FOR PREPARING HIGH PURITY 1alpha-HYDROXY VITAMIN D2 |
HUE032087T2 (en) | 2011-06-08 | 2017-08-28 | Kai Pharmaceuticals Inc | Serum Phosphor Control Therapy Device |
US20140315809A1 (en) | 2011-11-10 | 2014-10-23 | Kai Pharmaceuticals, Inc. | Calcimimetics and methods for their use |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
EP3193925A2 (en) | 2014-08-07 | 2017-07-26 | OPKO Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin d |
CN105348164B (zh) * | 2015-10-29 | 2017-03-29 | 无锡福祈制药有限公司 | 一种1α‑羟基维生素D2的制备方法 |
MX2018011820A (es) | 2016-03-28 | 2019-01-24 | Opko Ireland Global Holdings Ltd | Metodos de tratamiento con vitamina d. |
CN106748942B (zh) * | 2016-11-28 | 2018-06-29 | 无锡福祈制药有限公司 | 度骨化醇类似物wxfq-65及其合成方法 |
CN106748642B (zh) * | 2016-11-28 | 2019-11-05 | 无锡福祈制药有限公司 | 一种度骨化醇类似物wxfq-65的合成方法 |
JP6186532B1 (ja) * | 2017-03-31 | 2017-08-23 | ナガセ医薬品株式会社 | マキサカルシトール含有水溶液製剤 |
CN113666858A (zh) * | 2021-08-20 | 2021-11-19 | 江苏四环生物制药有限公司 | 一种度骨化醇及其制备方法 |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2383446A (en) * | 1941-06-04 | 1945-08-28 | Du Pont | Antirachitic materials and processes for their production |
US3697559A (en) * | 1971-02-25 | 1972-10-10 | Wisconsin Alumni Res Found | 1,25-dihydroxycholecalciferol |
US3741996A (en) * | 1971-12-02 | 1973-06-26 | Wisconsin Alumni Res Found | 1{60 -hydroxycholecalciferol |
US5472957A (en) * | 1973-01-10 | 1995-12-05 | Research Institute For Medicine And Chemistry | Chemical compounds and process |
US3907843A (en) * | 1974-06-14 | 1975-09-23 | Wisconsin Alumni Res Found | 1{60 -Hydroxyergocalciferol and processes for preparing same |
JPS5452717A (en) * | 1977-09-29 | 1979-04-25 | Chugai Pharmaceut Co Ltd | Stable oily pharmaceuticals containing 1alpha-hydroxyvitamin d |
US4202829A (en) * | 1978-01-05 | 1980-05-13 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxylated compounds |
US4195027A (en) * | 1978-01-16 | 1980-03-25 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxylated compounds |
US4260549A (en) * | 1979-05-21 | 1981-04-07 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxylated compounds |
US4160803A (en) * | 1978-03-23 | 1979-07-10 | Corning Glass Works | Self packaged test kit |
US4225596A (en) * | 1978-10-13 | 1980-09-30 | Wisconsin Alumni Research Foundation | Method for treating calcium imbalance and improving calcium absorption in mammals |
US4234495A (en) * | 1979-09-10 | 1980-11-18 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds |
US4362710A (en) * | 1980-07-04 | 1982-12-07 | Nissan Gosei Kogyo Co., Ltd. | Feeds for baby pigs, process for preparing the same and method of breeding baby pigs |
JPS57149224A (en) * | 1981-03-13 | 1982-09-14 | Chugai Pharmaceut Co Ltd | Tumor-suppressing agent |
ZA828012B (en) * | 1981-11-02 | 1983-09-28 | Res Inst Medicine Chem | Process for the preparation of 1-hydroxylated vitamin d compounds |
US4508651A (en) * | 1983-03-21 | 1985-04-02 | Hoffmann-La Roche Inc. | Synthesis of 1α,25-dihydroxyergocalciferol |
US4689180A (en) * | 1984-01-30 | 1987-08-25 | Wisconsin Alumni Research Foundation | 1α,25-dihydroxy-22Z-dehydroxyvitamin D compound |
US4588716A (en) * | 1984-05-04 | 1986-05-13 | Wisconsin Alumni Research Foundation | Method for treating metabolic bone disease in mammals |
US4554106A (en) * | 1984-11-01 | 1985-11-19 | Wisconsin Alumni Research Foundation | Method for preparing 1α-hydroxyvitamin D compounds |
US4555364A (en) * | 1984-11-01 | 1985-11-26 | Wisconsin Alumni Research Foundation | Method for preparing 1-hydroxyvitamin D compounds |
US5037816A (en) * | 1984-11-02 | 1991-08-06 | The General Hospital Corporation | Method of treating psoriasis |
US4728643A (en) * | 1984-11-02 | 1988-03-01 | The General Hospital Corporation | Method of treating psoriasis |
US4717721A (en) * | 1985-05-30 | 1988-01-05 | Howard W. Bremer | Sidechain homo-vitamin D compounds with preferential anti-cancer activity |
US4661294A (en) * | 1985-03-18 | 1987-04-28 | The General Hospital Corporation | Biologically active 1-thio derivatives of vitamin D |
IL78342A (en) * | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
JPH07100685B2 (ja) * | 1985-08-02 | 1995-11-01 | レオ・ファ−マシュ−ティカル・プロダクツ・リミテッド・エイ/エス(レ−ベンス・ケミスケ・ファブリック・プロデュクチオンスアクチ−セルスカブ) | 新規ビタミンd類似体 |
JPS62298572A (ja) * | 1986-06-19 | 1987-12-25 | Chugai Pharmaceut Co Ltd | 1α−ヒドロキシビタミンD3の精製法 |
US5554386A (en) * | 1986-07-03 | 1996-09-10 | Advanced Magnetics, Inc. | Delivery of therapeutic agents to receptors using polysaccharides |
US5527524A (en) * | 1986-08-18 | 1996-06-18 | The Dow Chemical Company | Dense star polymer conjugates |
US5338532A (en) * | 1986-08-18 | 1994-08-16 | The Dow Chemical Company | Starburst conjugates |
JPH0755960B2 (ja) * | 1986-11-14 | 1995-06-14 | 日清製粉株式会社 | ステロイド誘導体およびその製造方法 |
US4833125A (en) * | 1986-12-05 | 1989-05-23 | The General Hospital Corporation | Method of increasing bone mass |
JPH0714912B2 (ja) * | 1987-10-30 | 1995-02-22 | 日清製粉株式会社 | 1α−ヒドロキシビタミンD▲下2▼の製造方法 |
US4902481A (en) * | 1987-12-11 | 1990-02-20 | Millipore Corporation | Multi-well filtration test apparatus |
US5145846A (en) * | 1988-01-20 | 1992-09-08 | Hoffmann-La Roche Inc. | Vitamin D3 analogs |
US5087619A (en) * | 1988-01-20 | 1992-02-11 | Hoffman-La Roche Inc. | Vitamin D3 analogs |
JPH0637460B2 (ja) * | 1988-03-25 | 1994-05-18 | 帝国化学産業株式会社 | 1α―ヒドロキシ―ビタミンD▲下3▼の製造方法 |
JPH01246276A (ja) * | 1988-03-25 | 1989-10-02 | Teikoku Chem Ind Corp Ltd | 1α−ヒドロキシ―6―(1,3−ベンゾジチオール−2−イル)オキシー3,5−シクロビタミンD↓3 |
US5232836A (en) * | 1988-05-04 | 1993-08-03 | Ire-Medgenix S.A. | Vitamin D derivatives: therapeutic applications and applications to assays of metabolites of vitamin D |
US5104864A (en) * | 1988-08-02 | 1992-04-14 | Bone Care International, Inc. | Method for treating and preventing loss of bone mass |
US5602116A (en) * | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
US5098899A (en) * | 1989-03-06 | 1992-03-24 | Trustees Of Boston University | Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites |
CA1333616C (en) * | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
US5321018A (en) * | 1989-03-09 | 1994-06-14 | Wisconsin Alumni Research Foundation | Use of 1α-hydroxylated-19-nor-vitamin D compounds to treat psoriasis |
US5372996A (en) * | 1989-03-10 | 1994-12-13 | Endorecherche, Inc. | Method of treatment of androgen-related diseases |
US4948789A (en) * | 1989-03-28 | 1990-08-14 | Chugai Seiyaku Kabushiki Kaisha | Suppression of parathyroid hormone synthesis and secretion |
JP2645130B2 (ja) * | 1989-03-31 | 1997-08-25 | 日清製粉株式会社 | ステロイド誘導体 |
GB2229921B (en) * | 1989-04-05 | 1992-12-16 | Chugai Pharmaceutical Co Ltd | Treatment for hyperparathyroidism with use of vitamin d derivatives |
US5219528A (en) * | 1989-07-28 | 1993-06-15 | Pierce Chemical Company | Apparatus for rapid immunoassays |
DE3933034A1 (de) * | 1989-10-02 | 1991-04-11 | Schering Ag | 24-homo-vitamin-d-derivate, verfahren zu ihrer herstellung |
US5260290A (en) * | 1990-02-14 | 1993-11-09 | Wisconsin Alumni Research Foundation | Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5194248A (en) * | 1990-06-21 | 1993-03-16 | Trustees Of Boston University | Compositions comprising vitamin D analog precursors and the use thereof |
US5141719A (en) * | 1990-07-18 | 1992-08-25 | Bio-Rad Laboratories, Inc. | Multi-sample filtration plate assembly |
US5763428A (en) * | 1990-09-21 | 1998-06-09 | Bone Care International, Inc. | Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof |
CA2069084C (en) * | 1990-09-21 | 2007-05-22 | Joyce C. Knutson | 1.alpha.-hydroxy vitamin d4 and novel intermediates and analogues |
US6251883B1 (en) * | 1991-01-08 | 2001-06-26 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-dihydroxy vitamin D2 |
EP0550702B1 (en) * | 1991-01-08 | 1999-05-06 | Bone Care International, Inc. | METHODS FOR PREPARATION AND USE OF 1$g(a),24-DIHYDROXY VITAMIN D 2? |
DK0503630T3 (da) * | 1991-03-13 | 1996-01-29 | Kuraray Co | Cyclohexantriolderivater |
US5264184A (en) * | 1991-03-19 | 1993-11-23 | Minnesota Mining And Manufacturing Company | Device and a method for separating liquid samples |
NZ242271A (en) * | 1991-04-09 | 1993-10-26 | Takeda Chemical Industries Ltd | Medicaments containing a vitamin d compound stabilised by a basic substance |
US5417923A (en) * | 1991-04-24 | 1995-05-23 | Pfizer Inc. | Assay tray assembly |
DE69213844T2 (de) * | 1991-07-05 | 1997-04-10 | Duphar Int Res | Vitamin-D Derivat, Verfahren zu dessen Herstellung sowie Zwischenprodukte dafür |
US5205989A (en) * | 1991-09-18 | 1993-04-27 | Minnesota Mining And Manufacturing Company | Multi-well filtration apparatus |
JPH05339230A (ja) * | 1992-03-12 | 1993-12-21 | Nisshin Flour Milling Co Ltd | 活性型ビタミンd2及びその誘導体の製造法 |
JPH05320127A (ja) * | 1992-03-27 | 1993-12-03 | Nisshin Flour Milling Co Ltd | 活性型ビタミンd誘導体 |
US6113946A (en) * | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
US5962731A (en) * | 1992-04-22 | 1999-10-05 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
JP3722832B2 (ja) * | 1992-06-22 | 2005-11-30 | ルーナー、コーポレーション | 経口用1α−ヒドロキシプレビタミンD |
US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
DE4221961A1 (de) * | 1992-06-30 | 1994-01-05 | Schering Ag | 22-En-25-oxa-Derivate in der Vitamin D-Reihe, Verfahren zu ihrer Herstellung, diese Derivate enthaltenen pharmazeutische Präparate sowie deren Verwendung als Arzneimittel |
CA2121689C (en) * | 1992-08-28 | 2008-03-18 | Ronald L. Horst | 1.alpha.,24(s)-dihydroxy vitamin d2, its formation and use |
IL103224A (en) * | 1992-09-18 | 1998-08-16 | Teva Pharma | Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3 |
CA2096105A1 (en) * | 1992-10-07 | 1994-04-08 | Enrico Giuseppe Baggiolini (Deceased) | Vitamin d3 fluorinated analogs |
US5753638A (en) * | 1992-10-07 | 1998-05-19 | Hoffmann-La Roche Inc. | Method of treating hyperproliferative skin disease with Vitamin D3 fluorinated analogs |
US5247104A (en) * | 1992-11-04 | 1993-09-21 | Wisconsin Alumni Research Foundation | Preparation of 1α, 24-dihydroxyvitamin D analogs |
US5366965A (en) * | 1993-01-29 | 1994-11-22 | Boehringer Mannheim Gmbh | Regimen for treatment or prophylaxis of osteoporosis |
US5478816A (en) * | 1993-07-02 | 1995-12-26 | Bristol-Myers Squibb Company | Liquid vitamin formulations containing vitamin D esters |
PT667166E (pt) * | 1993-09-01 | 2001-02-28 | Teijin Ltd | Composicao de emulsao de 1alfa,24-(oh)2 vitamina d3 |
US5763429A (en) | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
US6103709A (en) * | 1993-12-23 | 2000-08-15 | The Regents Of The University Of California | Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs and methods for treatment of vitamin D diseases |
US5597575A (en) * | 1994-06-06 | 1997-01-28 | Breitbarth; Richard | Composition for stimulating and inducing hair growth |
JPH10506374A (ja) * | 1994-07-18 | 1998-06-23 | ボーン ケア インターナショナル インコーポレイテッド | 1α−ヒドロキシビタミンDの合成 |
US6242434B1 (en) * | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
US5739271A (en) * | 1995-06-07 | 1998-04-14 | Gen-Probe Incorporated | Thiocationic lipids |
US6221911B1 (en) * | 1995-06-07 | 2001-04-24 | Karo Bio Ab | Uses for thyroid hormone compounds or thyroid hormone-like compounds |
US5952317A (en) * | 1995-09-21 | 1999-09-14 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
JPH11514999A (ja) * | 1995-10-10 | 1999-12-21 | ストルーブ,マリリン | ビタミンdおよびその誘導体による掻痒症治療 |
EP0771789B1 (en) * | 1995-10-30 | 2000-02-16 | F. Hoffmann-La Roche Ag | 1 alpha, 26-dihydroxy-D-homo-vitamin D3 |
US5691328A (en) * | 1996-02-02 | 1997-11-25 | Clarion Pharmaceuticals Inc. | Phosphoethanolamine conjugates of vitamin D compounds |
AU710931B2 (en) * | 1996-02-28 | 1999-09-30 | Sumitomo Pharmaceuticals Company, Limited | Crystalline vitamin D derivative |
DK0892638T3 (da) * | 1996-04-04 | 2003-03-03 | Cilag Ag | Liposombaseret, topisk vitamin D-præparat |
DE19619036A1 (de) * | 1996-04-30 | 1997-11-13 | Schering Ag | Neue Vitamin D-Derivate mit carbo- oder heterocyclischen Substituenten an C-25, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln |
US5976784A (en) * | 1996-09-20 | 1999-11-02 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
US6599513B2 (en) * | 1997-05-27 | 2003-07-29 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
US6372234B1 (en) * | 1997-05-27 | 2002-04-16 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
US6359152B2 (en) * | 1997-07-21 | 2002-03-19 | Wisconsin Alumni Research Foundation | 18-substituted-19-nor-vitamin D compounds |
US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
WO1999049870A1 (en) * | 1998-03-27 | 1999-10-07 | Oregon Health Sciences University | Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders |
US6114317A (en) * | 1998-05-21 | 2000-09-05 | Wisconsin Alumni Research Foundation | Method of locking 1α-OH of vitamin D compounds in axial orientation |
US5972917A (en) * | 1998-05-29 | 1999-10-26 | Bone Care Int Inc | 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof |
US6552009B2 (en) * | 1998-07-16 | 2003-04-22 | Gentrix Llc | Compositions and methods of treating abnormal cell proliferation |
US20010002396A1 (en) * | 1998-07-16 | 2001-05-31 | Charles Achkar | Compositions and methods of treating skin conditions |
US6218430B1 (en) * | 1998-08-24 | 2001-04-17 | Ligand Pharmaceuticals Incorporated | Vitamin D3 mimics |
EP1123921A4 (en) * | 1998-10-23 | 2003-08-20 | Teijin Ltd | VITAMIN D 3 DERIVATIVES? AND MEDICINES FOR INFLAMMATORY RESPIRATORY DISEASES CONTAINING THEM |
US6432936B1 (en) * | 1999-01-20 | 2002-08-13 | Wisconsin Alumni Research Foundation | Crystalline 1α-hydroxyvitamin D2 and method of purification thereof |
US6548789B1 (en) * | 1999-04-22 | 2003-04-15 | Malden Mills Industries, Inc. | Electric resistance heating/warming fabric articles |
US6524594B1 (en) | 1999-06-23 | 2003-02-25 | Johnson & Johnson Consumer Companies, Inc. | Foaming oil gel compositions |
US6566554B1 (en) * | 1999-07-16 | 2003-05-20 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) | Aminobenzophenones as inhibitors of IL-1β and TNF-α |
US6555710B1 (en) * | 1999-07-16 | 2003-04-29 | Leo Pharmaceutical Products Ltd A/S Lovens Kemiske Fabrik Produktionsaktieselskab | Aminobenzophenones as inhibitors of IL-1 β and TNF-α |
DE19935771A1 (de) * | 1999-07-23 | 2001-02-01 | Schering Ag | Neue Vitamin D-Derivate mit cyclischen Substrukturen in den Seitenketten, Verfahren und Zwischenprodukte zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln |
FR2798855B1 (fr) | 1999-09-28 | 2003-04-25 | Oreal | Utilisation de complexes inorganiques-organiques dans une composition a usage topique |
WO2001025226A1 (en) * | 1999-10-05 | 2001-04-12 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
PL356049A1 (en) * | 1999-12-06 | 2004-06-14 | Leo Pharma A/S | Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
US6989377B2 (en) * | 1999-12-21 | 2006-01-24 | Wisconsin Alumni Research Foundation | Treating vitamin D responsive diseases |
US6251608B1 (en) * | 2000-04-20 | 2001-06-26 | Technion Research & Development Foundation, Ltd. | Method of determining a potential of a hyperglycemic patients of developing vascular complications |
AU2001260081B2 (en) | 2000-05-22 | 2005-07-28 | Leo Pharma A/S | Benzophenones as inhibitors of il-1beta and tnf-alpha |
US6395784B1 (en) | 2000-06-07 | 2002-05-28 | Bristol-Myers Squibb Company | Benzamide ligands for the thyroid receptor |
NZ528622A (en) * | 2000-06-15 | 2005-05-27 | Chugai Pharmaceutical Co Ltd | Methods for preparing vitamin D derivatives that are useful for treating psoriasis |
AU2001278956B2 (en) * | 2000-07-18 | 2007-04-05 | Genzyme Corporation | Stabilized 1alpha-hydroxy vitamin d |
IL155043A0 (en) * | 2000-09-22 | 2003-10-31 | Bristol Myers Squibb Pharma Co | Efficient process for preparation of a factor xa inhibitor |
US20030149005A1 (en) * | 2001-08-22 | 2003-08-07 | Posner Gary H. | 24-sulfur-substituted analogs of 1alpha, 25-dihydroxy vitamin D3 |
DE10156596A1 (de) * | 2001-11-13 | 2003-05-28 | Schering Ag | Vitamin D-Derivate mit Acyloxygruppen in der Seitenkette, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln |
-
2001
- 2001-07-18 AU AU2001278956A patent/AU2001278956B2/en not_active Ceased
- 2001-07-18 AU AU7895601A patent/AU7895601A/xx active Pending
- 2001-07-18 EP EP09002505A patent/EP2070911A2/en not_active Withdrawn
- 2001-07-18 JP JP2002512124A patent/JP2004504295A/ja active Pending
- 2001-07-18 IL IL15337801A patent/IL153378A0/xx active IP Right Grant
- 2001-07-18 WO PCT/US2001/022729 patent/WO2002006218A2/en active IP Right Grant
- 2001-07-18 CA CA002414407A patent/CA2414407A1/en not_active Abandoned
- 2001-07-18 EP EP01957187A patent/EP1301479A2/en not_active Withdrawn
-
2002
- 2002-08-20 US US10/223,986 patent/US6903083B2/en not_active Expired - Lifetime
- 2002-12-11 IL IL153378A patent/IL153378A/en not_active IP Right Cessation
-
2005
- 2005-02-24 US US11/065,429 patent/US20050148558A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004504295A5 (ja) | ||
AU2001278956B2 (en) | Stabilized 1alpha-hydroxy vitamin d | |
AU2001278956A1 (en) | Stabilized 1alpha-hydroxy vitamin d | |
EP3134393B1 (en) | Cyclohexenyl compounds, compositions comprising them and uses thereof | |
JP6289659B2 (ja) | 五環トリテルペン構造修飾化合物とその調製方法及び応用 | |
JPS61501088A (ja) | ヒドロキシビタミンd↓2異性体 | |
EP0792871A2 (en) | Crystalline vitamin D derivative | |
WO2012118154A1 (ja) | パーシャルアゴニスト活性を持つ新規ビタミンd受容体モジュレーター | |
WO2009062662A1 (en) | Pharmaceutical and nutraceutical compositions based on menaquinols | |
EP1007036A1 (en) | Methods of using butyric acid or butyric acid derivatives to protect against hair loss | |
JP2017534635A (ja) | レバプラザン塩酸塩の結晶多形及びその調製方法 | |
EP3026042B1 (en) | Stabilized 1,25-dihydroxyvitamin d2 and method of making same | |
JP6485836B2 (ja) | イグサ由来シクロオキシゲナーゼ−2阻害剤 | |
JP2687398B2 (ja) | アルドースリダクターゼ阻害剤 | |
JPH02142723A (ja) | 腎障害改善剤 | |
FR2518881A1 (fr) | Medicaments a base de 26,23-lactones de la 25-hydroxyvitamine d3, utiles notamment pour agir sur la concentration en calcium du serum | |
JPH01233217A (ja) | 糖尿病治療剤 | |
HU191681B (en) | Process for preparing pyridil-n-oxide-carboxylic acid esters and pharmaceutical preparations comprising the same as active substance | |
CN108503651B (zh) | 一种用于治疗脑卒中的螺环化合物 | |
EP0135510A1 (fr) | Nouveaux medicaments appartenant a la famille des derives d'halo genobenzophenone-oxime. | |
JPH01224367A (ja) | ポリアセチレン系化合物類、およびポリアセチレン系化合物類を有効成分とする5−リポキシゲナーゼ阻害剤 | |
JP4080567B2 (ja) | 新規ステロイド化合物およびこれを有効成分とするインターロイキン4産生抑制剤 | |
JPH03275698A (ja) | グリチルレチン酸代謝物およびグリチルレチン酸代謝物を有効成分とする3α―ヒドロキシステロイドデヒドロゲナーゼ阻害剤 | |
JP6998212B2 (ja) | ターメロンを有効成分とするβ‐セクレターゼ阻害剤、及び該阻害剤を含む飲食品 | |
JPH05301843A (ja) | 抗エイズ剤 |